The European Medicines Agency (EMA) means to increase first-in-man trial safety. Following the death of a volunteer in a Phase I trial earlier this year, the European Medicines Agency has started a review of the guidelines for first-in-man studies.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2016-05-31 18:42:002016-05-31 18:42:00EMA to make Phase I safer
A novel ophthalmic solution from R-Tech Ueno (Tokyo, Japan) made using Novozymes Biopharmas recombinant human albumin has recently obtained FDA approval to undergo Phase I/II clinical trials in the United States.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2016-05-29 18:36:002024-04-02 15:52:07Novozymes Biopharmas recombinant human albumin
The Finnish Technology Academy has awarded US-American innovator Frances Arnold the 2016 Millennium Technology Prize, worth €1m. Arnold is a pioneer in the field of directed evolution.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2016-05-27 18:44:002016-05-27 18:44:00Award and €1m for engineering pioneer
BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Seronos cilengitide as a multiple myeloma treatment.
Frode Marc Bohan has been reelected as Chairman of the Board of Directors for Norwegian Vitamin K2 expert NattoPharma ASA. He will continue to chair the board for the next two years.
https://european-biotechnology.com/wp-content/uploads/2024/04/epx_placeholder_610.png200610h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2016-05-25 21:17:002016-05-25 21:17:00Founder on board
One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2016-05-24 18:59:002016-05-24 18:59:00Financing for the gut
Swedish preeclampsia drug developer A1M Pharma has named Hungarian kidney specialist József Balla as the newest member of its scientific advisory board.
The long awaited global review on antimicrobial resistance by economist Lord Jim ONeill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2016-05-20 18:59:002016-05-20 18:59:00AMR Report: Test before you treat
Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.
EMA to make Phase I safer
Latest NewsThe European Medicines Agency (EMA) means to increase first-in-man trial safety. Following the death of a volunteer in a Phase I trial earlier this year, the European Medicines Agency has started a review of the guidelines for first-in-man studies.
Novozymes Biopharmas recombinant human albumin
ProductsA novel ophthalmic solution from R-Tech Ueno (Tokyo, Japan) made using Novozymes Biopharmas recombinant human albumin has recently obtained FDA approval to undergo Phase I/II clinical trials in the United States.
Award and €1m for engineering pioneer
Latest NewsThe Finnish Technology Academy has awarded US-American innovator Frances Arnold the 2016 Millennium Technology Prize, worth €1m. Arnold is a pioneer in the field of directed evolution.
BigDNA rebrands as Iceni
Latest NewsBigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Seronos cilengitide as a multiple myeloma treatment.
Founder on board
AppointmentsFrode Marc Bohan has been reelected as Chairman of the Board of Directors for Norwegian Vitamin K2 expert NattoPharma ASA. He will continue to chair the board for the next two years.
Financing for the gut
Latest NewsOne of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.
Scientific insight
AppointmentsSwedish preeclampsia drug developer A1M Pharma has named Hungarian kidney specialist József Balla as the newest member of its scientific advisory board.
CellBase CT system for improving Autologous Cell Therapies
ProductsTAP Biosystems installs CellBase CT system at PrimeCell to provide multiple Autologous Cell Therapies.
AMR Report: Test before you treat
Latest NewsThe long awaited global review on antimicrobial resistance by economist Lord Jim ONeill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.
CRISPR patent deal for Bayer
Latest NewsBayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.